HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 01.wnl.0000286942.14552.51v1 70/16_Part_2/1418    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wahner, A. D. Articles by Ritz, B. Search for Related Content PubMed PubMed Citation Articles by Wahner, A. D. Articles by Ritz, B. Related Collections Parkinson's disease/Parkinsonism Case control studies Risk factors in epidemiology

Statin use and the risk of Parkinson disease

From the Department of Epidemiology (A.D.W., B.R.), UCLA School of Public Health; and the Department of Neurology (J.M.B., Y.M.B.), David Geffen School of Medicine at UCLA and the Greater Los Angeles Veterans Administration Medical Center, Los Angeles, CA.

Address correspondence and reprint requests to Dr. Angelika D. Wahner, UCLA School of Public Health, Box 951772, 650 Charles E. Young Drive, Los Angeles, CA 90095-1772

Objective: To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).

Methods: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.

Results: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.

Conclusion: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.

GLOSSARY: B-D test = Breslow-Day test; NO = nitric oxide; PD = Parkinson disease; PEG = Parkinson's Environment and Genes.

awahner{at}ucla.edu

e-Pub ahead of print on January 9, 2008, at www.neurology.org.

Supported by NIH—National Institute of Environmental Health Sciences Grants ES10544, U54ES12078, and pilot funding received from the SCEHSC # 5P30 ES07048, the American Parkinson Disease Association, and the SW PADRECC Veterans Administration.

Disclosure: The authors report no conflicts of interest.

Received May 7, 2007. Accepted in final form August 14, 2007.

This article has been cited by other articles:

				A. Ghosh, A. Roy, J. Matras, S. Brahmachari, H. E. Gendelman, and K. Pahan Simvastatin Inhibits the Activation of p21ras and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease J. Neurosci., October 28, 2009; 29(43): 13543 - 13556. [Abstract] [Full Text] [PDF]